| 前收盘价格 | 7.14 |
| 收盘价格 | 7.21 |
| 成交量 | 201,376 |
| 平均成交量 (3个月) | 514,417 |
| 市值 | 332,977,440 |
| 价格/销量 (P/S) | 68.82 |
| 股市价格/股市净资产 (P/B) | 0.790 |
| 52周波幅 | |
| 利润日期 | 27 Mar 2025 |
| 营业利益率 (TTM) | -11,659.43% |
| 稀释每股收益 (EPS TTM) | -7.26 |
| 季度收入增长率 (YOY) | 79.70% |
| 总债务/股东权益 (D/E MRQ) | 6.07% |
| 流动比率 (MRQ) | 27.77 |
| 营业现金流 (OCF TTM) | -67.47 M |
| 杠杆自由现金流 (LFCF TTM) | -25.69 M |
| 资产报酬率 (ROA TTM) | -17.20% |
| 股东权益报酬率 (ROE TTM) | -27.05% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Septerna, Inc. | 看跌 | - |
AIStockmoo 评分
1.6
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.63 |
|
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 6.81% |
| 机构持股比例 | 102.74% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 50.00 (Cantor Fitzgerald, 568.45%) | 购买 |
| 中 | 30.50 (307.75%) | |
| 低 | 11.00 (Wells Fargo, 47.06%) | 保留 |
| 平均值 | 30.50 (307.75%) | |
| 总计 | 1 购买, 1 保留 | |
| 平均价格@调整类型 | 8.74 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wells Fargo | 28 Mar 2025 | 11.00 (47.06%) | 保留 | 6.10 |
| 18 Feb 2025 | 14.00 (87.17%) | 保留 | 6.87 | |
| Cantor Fitzgerald | 11 Feb 2025 | 50.00 (568.45%) | 购买 | 11.38 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合